H&O BIOSIS

On February 10, H&O Biosis (CEO Park Jong-Min and Hyun Ki-Woong, hereinafter referred to as H&O) announced that an integrated natural anticancer medicine under development was confirmed to have the apoptotic and antiproliferative effects on hepatocellular carcinoma cells in animal testing following in vivo and the results had been published in the scientific journal Cancers. - Heraldcorp.com - Established in 2019, H&O announced in 2020 that the results of in-vitro cell experiments show the effect of apoptosis and the inhibitory effect of proliferation in hepatocellular carcinoma cells on four types of liver cancer cell lines. Following this, in 2021, in-vitro results were shown to block metastasis of hepatoma cells and inhibit angiogenesis through additional experiments. In an animal experiment based on these experiments, not only did the growth of cancer cells of hepatoma cell line (Huh-7) decrease by about 50%, but also no peculiarities for toxicity were found in the blood test. The..

Also known as: H&O